AllAnalyst Report
logoMorningstarMarch 05, 2021

Danaher Corporation: Danaher Benefiting From COVID-19 Tailwinds in Life Sciences Business

Symbols
DHR
Sector(s)
Healthcare
Rating
Current Price
$248.31
Fair Value
Economic Moat
Stewardship
Summary

In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade

Analyst Profile

Julie Utterback

Senior Analyst
Julie Utterback is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers life sciences firms in the healthcare industry.Utterback initially joined Morningstar in 2005 as an equity analyst in the healthcare industry. At that time, she covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage on the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until rejoining the equity team in April 2019.Prior to joining Morningstar, Utterback was an equity analyst at State Farm Insurance for several years. She holds a bachelor's degree in finance from the University of Illinois Urbana- Champaign. She also holds the Chartered Financial Analyst® designation.